

PHARMACEUTICAL 2022

SELLAS Life Sciences Group Inc. Rank 271 of 466









PHARMACEUTICAL 2022



SELLAS Life Sciences Group Inc. Rank 271 of 466

The relative strengths and weaknesses of SELLAS Life Sciences Group Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SELLAS Life Sciences Group Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 31% points. The greatest weakness of SELLAS Life Sciences Group Inc. is the variable Expenses, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 89%, being 11% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	23,044
Cost of Goods Sold	200
Intangible Assets	1,914
Liabilities, Current	4,982
Liabilities, Non-Current	610
Other Assets	1,317
Other Compr. Net Income	0
Other Expenses	5,463
Other Liabilities	336
Other Net Income	4,358
Other Revenues	7,600
Property and Equipment	0
Research and Development	15,674
Selling, General and Administrative Expense	11,320

Output Variable	Value in 1000 USD
Assets	26,275
Liabilities	5,928
Expenses	32,657
Revenues	7,600
Stockholders Equity	20,347
Net Income	-20,699
Comprehensive Net Income	-20,699
Economic Capital Ratio	89%

